Research News and Research

RSS

Senate Subcommittee hearing looks at USAID budget request, potential for reform

A Senate Appropriations Subcommittee on State, Foreign Operations and Related Programs hearing on Tuesday about USAID's FY 2011 budget addressed the potential for "broad changes in the culture and operations of" USAID, CQ reports.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

COX-2 expression not an adequate independent prognostic factor: Research

Cyclooxygenase-2 represents a key modulatory molecule in inflammation and carcinogenesis. COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer.

22 Apr 2010

MRSA infections on the rise in hospitals and health care settings: AHRQ report

Despite activities to identify and reduce the spread of methicillin-resistant Staphylococcus aureus (MRSA) and other health care-associated infections in hospitals and health care settings nationwide, new reports released by the Agency for Healthcare Research and Quality show that MRSA is on the rise and continues to pose an alarming threat.

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Retired public employee's benefits in budget trimmers' sights

Miami Herald: "The [Florida] House dropped its plan to save $224 million by eliminating a monthly health insurance subsidy for about 300,000 retired public employees, many of them politically influential former teachers, police officers and firefighters. Axing the health subsidy for retirees had enraged public employee unions and Democrats, who accused Republicans of breaking a pact with public workers.

22 Apr 2010

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

A report released today by a federal working group highlights 11 key categories of diseases and other health consequences that are occurring or will occur due to climate change. The report, A Human Health Perspective on Climate Change, provides a starting point for coordination of federal research to better understand climate's impact on human health.

22 Apr 2010

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

In Colorado, "Gov. Bill Ritter signed four bills he promised will rein in skyrocketing health care costs on Tuesday and appointed a director who will oversee 10 state agencies to implement the Obama administration's new health care plan.

22 Apr 2010

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

The Society of Gynecologic Oncologists has published its second in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare."

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

22 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

Study links maternal height to children's health outcomes

Malnutrition suffered during a woman's childhood "can adversely affect the health of her children, Harvard researchers said Tuesday," following the release of their study in developing countries, which "found that the shortest women were substantially more likely to have children who died at an early age, who were underweight or who failed to thrive, according to a report in the Journal of the American Medical [Association]", the Los Angeles Times' blog "Shots" reports.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

Miller-McCune: 'Existing beliefs' can stand in the way of medical research

After a scientist found that runners' widespread habit of using ibuprofen before long races didn't help them, and may even cause more inflammation than doing nothing, a group of runners presented with the evidence still said they would continue using the drug, reports Miller-McCune, a Santa Barbara-based public policy magazine. The researcher who conducted the study said, "They really, really think it's helping. … Even in the face of data showing that it doesn't help, they still use it."

22 Apr 2010

Patient-physician compatibility affects adherence to doctor's orders, patient's health status: Study

Doctors and patients have varying opinions on how much control a person has over their own health outcomes. A new study by University of Iowa researchers suggests that when doctor and patient attitudes on the issue match up, patients do a better job of taking their medications.

22 Apr 2010

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Kathleen Keef, Ph.D., professor of physiology and cell biology at the University of Nevada School of Medicine, has been awarded a four-year, $1.2 million grant from the National Institute of Health to study the control of motility in the internal anal sphincter.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Medical technology innovation strives for personal focus, cost-efficiency

Medtronic CEO Bill Hawkins says the products made by his company, like pacemakers, insulin pumps and neurostimulators are the "ultimate personal technologies," according to CNNMoney. He said a shift in his industry is moving towards health information technology that people will depend on and use with their cell phones and laptops.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Research News and Research

Senate Subcommittee hearing looks at USAID budget request, potential for reform

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

COX-2 expression not an adequate independent prognostic factor: Research

MRSA infections on the rise in hospitals and health care settings: AHRQ report

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Retired public employee's benefits in budget trimmers' sights

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

Positive results from preclinical EP-302 program presented at AACR 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

Study links maternal height to children's health outcomes

Research findings may help personalize use of statins, scientists say

Miller-McCune: 'Existing beliefs' can stand in the way of medical research

Patient-physician compatibility affects adherence to doctor's orders, patient's health status: Study

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Medical technology innovation strives for personal focus, cost-efficiency

ImmunoCellular Therapeutics, UPENN sign research agreement

Spectroscopy Applications in the Environment eBook eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence